Phase I multicentre, open-label, dose-escalating study of PM00104 administered as 1 hour intravenous infusion every 3 weeks in subjects with advanced solid tumour or lymphoma

Trial Profile

Phase I multicentre, open-label, dose-escalating study of PM00104 administered as 1 hour intravenous infusion every 3 weeks in subjects with advanced solid tumour or lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2012

At a glance

  • Drugs PM 00104 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 26 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top